In this episode, Mattias Bernow, CEO of Cellcolabs, joins The Beyond Tomorrow Podcast to explore the future of regenerative medicine and its real, science-backed potential. This conversation dives deep into the actual science of stem cells. Mattias Bernow explains how stem cell therapies could become mainstream tools for fighting chronic diseases, boosting longevity, and improving healthspan.

Key Points:

Stem cells could soon become routine medicine, delaying disease and enhancing healthy lifespan. Bernow explains how stem cells may become the “antibiotics for chronic disease,” reshaping everything from arthritis to Alzheimer’s care. With cautious optimism, he stresses the importance of quality, safety, and evidence in advancing the field.

• Stem Cells: The “Next Antibiotics” for Chronic Disease: Mattias Bernow explains how mesenchymal stem cells (MSCs) may do for chronic diseases what antibiotics did for infections—offering prevention and repair for conditions like heart disease, arthritis, and Alzheimer’s.
• What MSCs Really Do: MSCs aren’t miracle cures. They work by reducing inflammation, promoting tissue regeneration, and modulating immune response—without permanently integrating into the body (they don’t “engraft”).
• Mattias’s Journey- From Emergency Medicine to Cellcolabs CEO: Coming from a family of doctors, Bernow combined clinical and business expertise to lead Cellcolabs—a company dedicated to making high-quality, GMP-certified stem cells affordable and accessible globally.
• Separating Science from Hype: The industry is plagued by unregulated “stem cell clinics.” Bernow warns against substandard treatments and emphasizes the need for GMP (Good Manufacturing Practice) certified cells and responsible clinical use.
• Real-World Evidence & Clinical Promise: Early trials show MSCs may help treat arthritis, cardiovascular conditions, and inflammatory bowel disease—and potentially slow aging-related decline. Patients may experience benefits lasting 6–18 months from a single treatment.
• Why Quality Matters- GMP is Non-Negotiable: Bernow urges anyone considering stem cell therapy to verify GMP certification. High-quality manufacturing ensures safety, efficacy, and helps protect the reputation of the entire field.
• The Future- Widespread, Regulated Access in 5–10 Years: With shifting global regulations (led by Japan, South Korea, and the US), Bernow predicts stem cell therapy could become part of routine check-ups—like annual flu shots—by 2035.
• Not Immortality, But Better Healthspan: Bernow doesn’t claim stem cells will help us live to 200. Instead, he believes their greatest promise lies in extending healthy, functional years—delaying or preventing chronic diseases before they start.